ImacevaTM
Imatinib
Tyrosine kinase inhibitor (Oncology)
Indication:
ImacevaTM is indicated for the treatment of: • Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase. Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. • Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL). Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) in combination with chemotherapy. • Adult patients with myel.
Dosage & Administration:
The recommended dose for Imatinib are: • Adults with Ph+CML CP: 400 mg/day; • Adults with Ph+CML AP or BC: 600 mg/day; • Pediatrics with Ph+CML CP: 340 mg/m2/day; • Adults with Ph+ALL: 600 mg/day; • Pediatrics with Ph+ALL: 340 mg/m2/day; •Adults with MDS/MPD: 400 mg/day; • Adults with ASM: 100 mg/day or 400 mg/day; • Adults with HES/CEL: 100 mg/day or 400 mg/day; • Adults with DFSP: 800 mg/day; • Adults with metastatic and/or unresectable GIST: 400 mg/day; • Adjuvant treatment of adults with GIST: 400 mg/day; • Patients with mild to moderate hepatic impairment: 400 mg/day; • Patients with severe hepatic impairment: 300 mg/day.
Preparation:
ImacevaTM 100: Each box contains 3 blister of 10 tablets.
ImacevaTM 400: Each box contains 3 blister of 10 tablets.
